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Quantitative Evaluation of Drug or Device
Effects on Ventricular Remodeling as Predictors
of Therapeutic Effects on Mortality in Patients
With Heart Failure and Reduced Ejection Fraction
A Meta-Analytic Approach
Daniel G. Kramer, MD,* Thomas A. Trikalinos, MD, PHD,† David M. Kent, MD, MS,†
George V. Antonopoulos, MD,* Marvin A. Konstam, MD,* James E. Udelson, MD*
Boston, Massachusetts
Objectives The purpose of this study was to quantitatively assess the relationship between therapy-induced changes in left
ventricular (LV) remodeling and longer-term outcomes in patients with left ventricular dysfunction (LVD).
Background Whether therapy-induced changes in left ventricular ejection fraction (LVEF), end-diastolic volume (EDV), and
end-systolic volume (ESV) are predictors of mortality in patients with LVD is not established.
Methods Searches for randomized controlled trials (RCTs) were conducted to identify drug or device therapies for which
an effect on mortality in patients with LVD was studied in at least 1 RCT of 500 patients (mortality trials).
Then, all RCTs involving those therapies were identified in patients with LVD that described changes in LVEF
and/or volumes over time (remodeling trials). We examined whether the magnitude of remodeling effects is as-
sociated with the odds ratios for death across all therapies or associated with whether the odds ratio for mortal-
ity was favorable, neutral, or adverse (i.e., statistically significantly decreased, nonsignificant, or statistically sig-
nificantly increased odds for mortality, respectively).
Results Included were 30 mortality trials of 25 drug/device therapies (n  69,766 patients; median follow-up
17 months) and 88 remodeling trials of the same therapies (n  19,921 patients; median follow-up 6 months).
The odds ratio for death in the mortality trials was correlated with drug/device effects on LVEF (r  0.51,
p  0.001), EDV (r  0.44, p  0.002), and ESV (r  0.48, p  0.002). In (ordinal) logistic regressions, the odds
for neutral or favorable effects in the mortality RCTs increased with mean increases in LVEF and with mean de-
creases in EDV and ESV in the remodeling trials.
Conclusions In patients with LVD, short-term trial-level therapeutic effects of a drug or device on LV remodeling are associ-
ated with longer-term trial-level effects on mortality. (J Am Coll Cardiol 2010;56:392–406) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.011n
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fhile the past 2 decades have seen important advances in
herapies for heart failure (HF) (1), there have also been
ome promising agents—endothelin antagonists (2,3), cy-
okine inhibitors (4), and vasopeptidase inhibitors (5,6)—
eveloped through phase 3 clinical testing only to yield
rom the *Division of Cardiology and the CardioVascular Center, Tufts Medical
enter, and the †Center for Clinical Evidence Synthesis, Institute for Clinical
esearch and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.
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linical and Translational Science Institute. Dr. Konstam is a consultant for
oehringer-Ingelheim, Trevena, Johnson & Johnson, Cardioxyl, Merck, and Forest.
r. Udelson is a consultant for Cytori, Angioblast, and Medtronic.s
Manuscript received December 28, 2009; revised manuscript received May 3, 2010,
ccepted May 18, 2010.egative or neutral results. Because phase 3 trials are by far
he most costly and time-consuming phase of drug devel-
pment, minimization of potential negative or null results is
mportant for the development of new therapies. Thus, it
ould be very helpful to obtain an early signal of clinical
fficacy in the context of shorter, smaller phase 2 trials.
Assessment of ventricular remodeling (i.e., characteristic
hanges in ventricular volume and wall thickness and shape)
s often referred to as a potential surrogate end point for
rug or device effects on HF outcomes (1,7). Left ventric-
lar end-diastolic volume (EDV) and end-systolic volume
ESV) (8), dimensions (9,10), and left ventricular ejection
raction (LVEF) (11–14) are each prognostic when mea-
ured at 1 point in time for subsequent mortality risk.
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July 27, 2010:392–406 Ventricular Remodeling and Ef fects on Mortalityoreover, data from some HF trials of individual therapeu-
ic agents suggest a relation between a drug or device effect
n remodeling and the therapeutic effect on natural history
utcome (9,10,15). How well therapy-induced changes in
hese parameters predict therapeutic benefit in mortality
utcomes, independent of an individual therapy, has not
een quantitatively assessed. Herein, we systematically eval-
ate the degree to which therapy-induced changes in 3
easures often assessed in remodeling studies (LVEF,
DV, and ESV) are associated with therapeutic effect on
ortality outcomes in phase 3 clinical trials in patients with
F and left ventricular dysfunction (LVD).
ethods
eneral approach. Ideally, the assessment of the relation
etween the effect of a therapy on remodeling and its effect
n mortality would be evaluated in large adequately powered
utcome trials, in which all of the patients also had early
ssessment of remodeling by noninvasive imaging. How-
ver, given the expense and complexity of imaging in such a
etting, very few trials have included measures of remodel-
ng in all patients, with some exceptions (3,16–19). More
ften, remodeling is assessed in a substudy population
elected from the overall population sample of a trial
20–25) or hypotheses are formed based on the results of
utcome studies along with smaller remodeling studies from
istinct samples of patients (26). We initially identified
rom the literature drugs or devices for HF patients that
ere studied in large randomized controlled trials (RCTs)
valuating mortality. Then, we systematically identified
rom the published literature effects of those drugs and
evices on remodeling parameters from imaging studies,
nd examined associations between trial-level (mean)
hanges in the remodeling outcome and effects on mortality
ith the same drug or device.
dentification of eligible interventions. We first per-
ormed a systematic literature search to identify all drug and
evice therapies for patients with LVD, for which mortality
as evaluated in at least 1 large placebo-controlled RCT
ith adequate follow-up. For all treatments identified in
his set of RCTs (subsequently referred to as “mortality”
CTs), we systematically identified all published placebo-
ontrolled RCTs describing the effects of those treatments
n parameters of LV remodeling (subsequently referred to
s “remodeling” trials).
earch strategy. We performed several incremental and
verlapping MEDLINE searches (covering January 1966
hrough April 16, 2007) using the keywords “heart failure”
nd “double-blind” and “placebo.” We first identified qual-
fying mortality trials that identified the interventions for
hich a search for remodeling trials was required. The
earch strategy for the remodeling trials was performed in 2
teps (1966 to 1999 [27] and January 1, 1999, to April 16,
007). We limited searches to English language peer-
eviewed publications on human subjects. Double-blind pnalysis was a requisite for all
tudies, except for the device
rials.
Thorough examination of ci-
ation lists from all retrieved
tudies, meta-analyses and re-
iew articles was conducted to
dentify additional relevant pub-
ications. We complemented
earches with input from field
xperts. Only published studies
n peer-reviewed journals were
ncluded. Care was taken to in-
lude only the most recent or
ost complete data in the case of
verlapping and duplicated data
ets. Data from review articles,
ase reports, abstracts, reports of
rial presentations at conferences,
nd data from letters were not
ncluded.
ligibility criteria. All included
rials were English language, double-blind (except device
rials), randomized, placebo-controlled trials on human
ubjects with LVEF 45%. For mortality trials, we pro-
pectively required at least 500 patients and at least 6
onths of follow-up for eligibility. For remodeling trials,
e required the measurement of at least 1 measure of
entricular remodeling (LVEF, volume, or dimension) in
ctive drug and placebo groups over a period of at least 4
eeks, an arbitrary cut-point meant to eliminate very
hort-term studies of acute effects. There was no minimum
ample size for the remodeling trials.
ata extraction. A single investigator (D.G.K.) extracted
ata on pre-constructed paper forms, receiving input from
n experienced methodologist when needed. Information
n the publication, the active intervention, and patient
haracteristics from each trial were extracted. Mean
ollow-up duration and the number of patients enrolled and
nalyzed per study arm were recorded.
For each arm in the mortality trials, the number of deaths
rom all causes was extracted. For the remodeling trials, we
ecorded information necessary to calculate the mean net
ifference in LVEF, EDV, ESV, or dimensions over time
cross the compared randomized arms (28). Typically, this
nvolved recording the means and standard deviations of the
ertinent measures before and after treatment.
alculation of trial-level (mean) effects on mortality and
emodeling outcomes. For each intervention, we calcu-
ated the odds ratio (OR) for long-term all-cause mortality.
hen multiple studies existed, we derived summary effects
sing standard meta-analysis, the Mantel-Haenszel method
or 2 studies (29) and the DerSimonian and Laird random
ffects method for 3 studies (30). We tested for hetero-
eneity with the Q statistic (considered significant for
Abbreviations
and Acronyms
AUC  area under the
curve
CI  confidence interval
EDV  end-diastolic volume
ESV  end-systolic volume
HF  heart failure
IQR  interquartile range
LVD  left ventricular
dysfunction
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
OR  odds ratio
RCT  randomized
controlled trial
ROC  receiver-operating
characteristic 0.10) (31) and calculated its extent with I2 (32). The I2
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Ventricular Remodeling and Ef fects on Mortality July 27, 2010:392–406xpresses the proportion of between-study variability that is
ttributed to heterogeneity rather than chance, with values
50% indicating high heterogeneity (33).
From each remodeling trial, we calculated the mean net
ifference of the change in the LVEF, EDV, and ESV over
ime between intervention and placebo groups. As described
n the following text under “Correlation and regression
nalyses,” main analyses considered effects from the remod-
ling trials separately. To be inclusive of as much extant
ublished data as possible, we prospectively elected to also
nclude data from studies that published results of LV
imensions instead of calculated LV volumes. For remod-
ling trials that reported only LV dimensions, we trans-
ormed mean changes (and variances thereof) in LV dimen-
ions to the corresponding mean changes (and variances) of
V volumes, by using the delta method (34) and the
eicholtz formula (35). Similarly, mean changes (and vari-
nces) in LV ESV and EDV indices were transformed to
V volumes using the Mosteller formula for the body
urface area (36) and assuming a height of 1.70 m and a
eight of 75 kg. The latter are approximates of the median
ex-averaged values in the U.S. population aged similarly to
he mean ages in our eligible studies (37). Results were not
ensitive to small perturbations in these somatometric as-
umptions (data not shown). We assessed the validity of the
ransformations in 5 studies reporting 8 pairs of mean
hanges both in diameters/indices and in volumes. Discrep-
ncies between the estimated (transformed) and actual mean
hanges were 10 ml in 4 measurements (maximum dis-
repancy approximately 25 ml in EDV). The transformed
alues were less extreme than the actual values in 7 of 8 pairs
nd always smaller than 10 ml. This finding suggests that
he transformations bias findings toward the null.
orrelation and regression analyses. For each of the 3
emodeling outcomes (LVEF, EDV, and ESV), main
nalyses were performed in 3 steps. All main analyses were
nadjusted and considered remodeling effects from trials on
he same intervention separately. First, we calculated un-
eighted Spearman correlations between the trial-level
emodeling effects and the corresponding summary OR for
ortality. These analyses are largely descriptive as they do
ot account for the statistical errors that accompany the
ortality and remodeling effect estimates.
Second, we explored whether there is a simple linear
elationship between the log-transformed OR for mortality
nd the magnitude of the remodeling effects using a general
inear model that accounts for heteroskedasticity in the
ependent variable (inverse variance weighting) and the
lustering of observations by intervention (with robust
tandard error estimation). This analysis yields the relative
R for mortality per given change in the remodeling
arameter.
Third, we examined with logistic and ordinal logistic
egressions whether remodeling outcomes can predict
hether the OR for mortality was favorable, neutral, ordverse (i.e., statistically significantly decreased, nonsignif- icant, or statistically significantly increased odds for mortal-
ty, respectively) with the corresponding intervention. An
ntervention was considered to have a favorable mortality
ffect if the upper bound of the 95% confidence interval (CI)
f the OR was 1, a neutral mortality effect if the 95% CI
f the OR included 1, and an adverse mortality effect if the
ower bound of the 95% CI of the OR was 1. Again, we
sed inverse variance weighting and accounted for clustering
f observations by intervention with robust standard error
stimation. This alternative analysis categorizes the effect on
ortality into 3 ordinal categories, and informs on the
bility of short-term remodeling outcomes to predict effects
n mortality in larger trials.
For illustrative purposes, we plotted predicted probabili-
ies for favorable, neutral, or adverse effects on mortality for
ifferent magnitudes of remodeling effects, and produced
eceiver-operating characteristic (ROC) curves. The area
nder the ROC curve (AUC) is a simple measure of the
iscriminatory ability of the mean change in the remodeling
utcomes to predict mortality. It represents the percentage
f all possible discordant pairs of interventions discordant
or their mortality effects in which the variable (change in
VEF, EDV, or ESV, respectively) and correctly assigns a
igher probability of mortality benefit to the intervention
hat actually demonstrated benefit. An AUC value of 0.5
mplies no discriminatory ability, and an AUC value of 1.0
mplies perfect discrimination.
ensitivity analyses. In sensitivity analyses, regressions
ere adjusted for the mean value of the remodeling outcome
t baseline and for follow-up duration. We also repeated all
egression analyses using unweighted regressions, and after
liminating the shorter-term remodeling studies (12
eeks of follow-up). We performed main analyses excluding
tudies where we calculated values of changes in ESV and
DV from results on diameters or indices. Finally, addi-
ional sensitivity analyses used the meta-analysis-derived
ummary effect size of all remodeling trials within each
rug/device intervention, rather than considering remodel-
ng trials separately (as was done in the main analyses).
All analyses and graphs were performed in Stata SE
ersion 11 (Stata Corp., College Station, Texas) and in
eta-Analyst (Tufts Evidence-based Practice Center,
009). Unless otherwise stated, all p values are 2-tailed and
onsidered significant at the 0.05 level.
esults
esults of search algorithms. The search algorithm
ielded 1,992 citations, and 248 articles were retrieved and
eviewed in full text. In total, 117 nonoverlapping RCT
eports were eligible. We identified 30 large RCTs describ-
ng the effects of 25 different interventions on mortality
Fig. 1A) that reported on a total of 69,766 patients over a
edian follow-up of 17 months. For each individual drug/
evice intervention for which a mortality trial had been
dentified, we identified between 1 and 22 remodeling trials.
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July 27, 2010:392–406 Ventricular Remodeling and Ef fects on Mortalityhere were 88 remodeling RCTs evaluating 91 distinct
rug or device versus placebo comparisons, involving 19,921
atients with median follow-up of 6 months (Fig. 1B). Four
f the 30 mortality trials reported serial measurements of
emodeling parameters of all patients and, therefore, also
ualified as remodeling trials (16,17,19,38), whereas 11 other
emodeling trials were substudies of 1 of the mortality RCTs
20–22,25,39–45). To assess remodeling, 39 trials employed
adionuclide ventriculography, 32 utilized 2-dimensional
chocardiography, and 3 utilized magnetic resonance imag-
ng. Fourteen studies used a combination of radionuclide
entriculography and 2-dimensional echocardiography.
ffect on drug or device therapies on mortality. Table 1
escribes the effects of the 25 distinct drug/device therapies
n mortality (4,16–19,44,46–67). Nine, 12, and 4 inter-
entions had significantly favorable, neutral, and signifi-
antly adverse effects on mortality, respectively, in the
dentified trials. The mortality trials included predominantly
ale patients (81% on average) with mean ages between 57
nd 67 years (median age 63 years). Mean New York Heart
ssociation (NYHA) HF functional class was 2.7 (inter-
Figure 1 Search Pathway for Identifying Mortality and Remode
(A) Search pathway for identification of mortality trials. (B) Search pathway for ide
evaluated 91 drug-placebo comparisons (86 parallel arm trials; 3 trials evaluateduartile range [IQR] 0.7). The median number of patients ier individual drug/device intervention was 2,345 (IQR
,328). The 30 trials followed up patients for a median of 17
onths. Two (6%) of the trials evaluated patients with
VD after an acute myocardial infarction; the remaining 29
94%) trials evaluated patients with chronic HF and LVD.
Of note, we chose to evaluate the use of enalapril to treat
symptomatic LV dysfunction as a separate entity, as this
as the only trial in which all of the patients studied had
YHA functional class I HF (57).
ffect on drug or device therapies on remodeling. We
dentified 88 remodeling RCTs that included a total of
9,741 patients (median 53 patients per trial; IQR 133) in
hich the effect of the 25 drug or device therapies (identi-
ed from the mortality trials) on remodeling was evaluated.
he majority (n 85 trials) were parallel arm trials, whereas
he remaining 3 trials examined 2 separate drugs versus a
ingle placebo arm. The remodeling trials included predom-
nantly male patients (57% in all trials), with mean ages
etween 45 and 71 years (median 60 years). Mean NYHA
F functional class was 2.5 (IQR 0.7). Nine (10%) of the
rials evaluated patients with LVD after an acute myocardial
rials
tion of remodeling trials. *In all, 88 trials
s vs. placebo). RCT  randomized controlled trial.ling T
ntifica
2 drugnfarction; the remaining 82 (90%) trials evaluated patients
w
m
M
s
f
s
t
L
p
e
C
c
t
t
t
p
B
E
0
f
t
a
e
o
2
c
F
a
i
A
g
w
C
c
t
t
s
c
d
t
p
a
i
f
d
c
a
d
f
C
c
w
T
m
s
t
f
c
a
t
F
e
e
f
n
d
E
n
w
p
S
E
i
t
(
DP
*
d
a
m
I
396 Kramer et al. JACC Vol. 56, No. 5, 2010
Ventricular Remodeling and Ef fects on Mortality July 27, 2010:392–406ith chronic HF. While the average follow-up was 6
onths; 81 trials (89%) had a follow-up of 12 weeks.
Mean changes in the LVEF were extracted from 86 trials.
ean changes in EDV and ESV were extracted from only 14
tudies; we calculated mean changes in the EDV and ESV
rom corresponding changes in diameters or indices in 35 of 49
tudies and 26 of 40 studies reporting pertinent data, respec-
ively. Tables 2, 3, and 4 describe the summary net changes in
VEF, EDV, and ESV for the 25 eligible interventions com-
ared with placebo (16,17,19–25,38–45,49,68–139). For sev-
ral interventions, between-study heterogeneity was extensive.
hange in LVEF and long-term mortality. Placebo-
orrected change in LVEF from each individual remodeling
rial was plotted against the mortality OR for the specific
herapy. There was a significant correlation between short-
erm therapeutic effect on LVEF and longer-term thera-
eutic effect on mortality (r0.51, p 0.001) (Fig. 2A).
ased on the regression analyses, a 5% increase in the mean
F change corresponded to a relative OR of 0.86 (95% CI:
.77 to 0.96) for mortality, in other words, toward the
avorable direction (p  0.013).
We also evaluated the ability of mean changes in LVEF
o categorize interventions as significantly favorable, neutral,
rug/Device Effects of Mortality Compared Withlacebo in Patients With He rt Failure nd LVDTable 1 Drug/Dev ce Effec s of Mortality Compared WithPlacebo in Patients With Heart Failure and LVD
Intervention (Ref. #) No. of Studies (n) OR† (95% CI)
Amiodarone (17) 1 (674) 0.87 (0.64–1.19)
Amlodipine (46) 1 (1,153) 0.80 (0.63–1.02)
Bucindolol (19) 1 (2,708) 0.88 (0.75–1.03)
Bisoprolol (47) 1 (2,647) 0.64 (0.51–0.79)
CRT (48) 2 (1,738) 0.69 (0.51–0.94)
Candesartan (49,50) 2 (4,576) 0.83 (0.73–0.95)
Captopril (51) 1 (2,231) 0.79 (0.64–0.96)
Carvedilol (52–54) 3 (5,342) 0.62 (0.47–0.81)
Digoxin (55) 1 (6,800) 0.99 (0.89–1.09)
Enalapril (56) 1 (2,569) 0.82 (0.70–0.97)
Enalapril-Prev (57)* 1 (4,228) 0.93 (0.79–1.10)
Enoximone (58) 1 (1,854) 0.95 (0.76–1.18)
Etanercept (4) 1 (2,356) 1.22 (0.93–1.61)
Felodipine (59) 1 (450) 1.07 (0.62–1.84)
Flosequinan (60) 1 (2,345) 1.42 (1.15–1.76)
Hydralazine-ISDN (16,61) 2 (1,509) 0.70 (0.51–0.96)
Ibopamine (62) 1 (1,906) 1.27 (1.02–1.57)
Metoprolol CR (63) 1 (3,991) 0.67 (0.54–0.83)
Mibefradil (44) 1 (2,571) 1.14 (0.96–1.36)
Milrinone (64) 1 (1,088) 1.35 (1.03–1.76)
Moxonidine (65) 1 (1,934) 1.64 (1.05–2.57)
Prazosin (16) 1 (456) 1.26 (0.87–1.84)
Spironolactone (66) 1 (1,663) 0.62 (0.51–0.76)
Tolvaptan (67) 1 (4,134) 0.98 (0.85–1.12)
Valsartan (18) 1 (5,010) 1.02 (0.89–1.18)
Enalapril was examined separately when studied in patients with asymptomatic left ventricular
ysfunction (LVD), as this was the only trial which exclusively examined patients with asymptom-
tic LVD. †When 1 trial existed for a specific therapy, meta-analysis was used to calculate the
ortality odds ratio (OR).
CI  confidence interval; CR  controlled release; CRT  cardiac resynchronization therapy;
SDN  isosorbide dinitrate; Prev  Studies of Left Ventricular Dysfunction Prevention trial.nd significantly adverse, according to each intervention’s vffect on mortality. We found a 4.9-fold increase in the odds
f having a favorable mortality outcome (95% CI: 1.2 to
0.3, p  0.029) for every 5% absolute increase in the mean
hange in the EF (weighted ordinal logistic regression).
igure 2B shows the predicted probabilities for the effect of
given intervention on long-term mortality based on an
ntervention’s average effect on EF. In ROC analysis, the
UC for a drug/device-induced change in LVEF to distin-
uish favorable from neutral or adverse mortality outcomes
as 0.71.
hange in LV EDV and long-term mortality. Placebo-
orrected change in EDV from each individual remodeling
rial was plotted against the mortality OR for the specific
herapy. There was a significant correlation between effect
izes in the mortality trials and mean therapy-induced
hanges in EDV (r  0.44, p  0.002) (Fig. 3A). A
ecrease of 10 ml in the mean change in EDV corresponded
o a relative OR of 0.95 for mortality (95% CI: 0.94 to 0.97,
 0.001).
A decrease of 10 ml in the mean change of EDV was
ssociated with 1.9-fold (95% CI: 1.2 to 3.2, p  0.012)
ncreased odds that an intervention would have significantly
avorable effects on mortality. Figure 3B shows the pre-
icted probability for therapeutic effects on mortality ac-
ording to an intervention’s average effect on EDV. In ROC
nalysis, the AUC for a net change in LV EDV to
istinguish favorable from neutral or adverse outcome ef-
ects of therapies was 0.76.
hange in LV ESV and long-term mortality. Placebo-
orrected change in ESV from each individual remodeling trial
as plotted against the mortality OR for the specific therapy.
here was a significant correlation between effect sizes in the
ortality trials and the effect sizes on ESV in the remodeling
tudies (r  0.48, p  0.002) (Fig. 4A). A decrease of 10 l in
he mean ESV change corresponded to a relative OR of 0.96
or mortality (95% CI: 0.93 to 0.98, p  0.01).
Logistic regression analyses suggested a significant asso-
iation between the mean change in ESV due to therapy
nd effects on mortality, based on a per 10-ml decrease in
he mean change in ESV (OR: 0.56, 95% CI: 0.53 to 0.60).
igure 4B shows the predicted probability for favorable
ffects on mortality according to an intervention’s average
ffect on ESV. In ROC analysis, the AUC to distinguish
avorable from neutral or adverse therapies was 0.73. It is
oted from Table 4 that there are fewer published data on
rug/device effects on ESV compared to data on LVEF or
DV, particularly for interventions that were found to have
eutral or adverse mortality effects. For this reason, there
as insufficient remodeling data for ESV to model the
robability for neutral or adverse outcomes individually.
econdary analyses. Adjustments for the average LVEF,
DV, or ESV at baseline (as applicable in the correspond-
ng analyses) and follow-up duration in the remodeling
rials resulted in very similar estimates as the main analysis
data not shown). The same was true for the unweighted
ersions of the regression analyses. Eliminating the shorter-
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July 27, 2010:392–406 Ventricular Remodeling and Ef fects on Mortalityerm remodeling studies (6 studies in which the follow-up was
12 weeks) resulted in very similar correlation estimates
etween the mortality OR and the placebo-corrected change in
emodeling outcomes, without inferential changes (EF0.51,
 0.001; EDV 0.40, p  0.009; ESV 0.44, p  0.007).
Mean changes in EDV and ESV (without transformation
rom dimensions) were reported only in 14 studies. We
alculated mean changes in the EDV from corresponding
hanges in diameters or indices for 35 of 49 studies, and in
SV for 26 of 40 studies with available data. After exclud-
ng studies in which we performed transformations, all
esults of the ESV and EDV metrics became statistically not
ignificant, with substantial loss of data.
Results similar to the main analysis were seen when we
sed meta-analysis–derived summary estimates of the ef-
ects on LVEF, EDV, and ESV, instead of considering
ultiple studies on the same intervention separately. How-
ver, the correlation between long-term effects on mortality
nd ESV was no longer significant (p  0.09).
iscussion
he results of the present study demonstrate a significant
ssociation between short-term trial-level therapeutic effects
Absolute Effect of Drug/Device on Change in EF CTable 2 Absolute Effect of Drug/Device on C
Intervention (Ref. #)
No. of Stud
(n [Range
Amiodarone (17,68,69) 3 (942 [30–67
Amlodipine (70) 1 (362)
Bisoprolol (41) 1 (28)
Bucindolol (19,71–73) 4 (2,915 [19–
CRT (74–77) 4 (1,052)
Candesartan (78) 1 (305)
Captopril (79–84) 6 (543 [40–20
Carvedilol (23,24,49,85–104) 22 (2,780 [15–
Digoxin (84,105–109) 6 (624 [13–19
Enalapril (20,42,110–113) 6 (431 [12–30
Enalapril-Prev (21)* 1 (108)
Enoximone (114–119) 6 (203 [12–11
Etanercept (120) 1 (47)
Felodipine (43,121,122) 3 (532 [20–26
Flosequinan (123,124) 2 (210 [17–19
Hydralazine-ISDN (16,22) 2 (1,137 [459
Ibopamine (125) 1 (18)
Metoprolol CR (39,40,126,127) 4 (587 [41–42
Mibefradil (44) 1 (117)
Milrinone (109) 1 (108)
Moxonidine (128) 1 (85)
Prazosin (16,129–131) 4 (523 [22–45
Spironolactone (132–134) 3 (185 [37–10
Tolvaptan (45) 1 (240)
Valsartan (38) 1 (5,010)
*Enalapril was examined separately when studied in patients with asy
with asymptomatic LVD. †When 1 trial existed for a specific therap
fraction (EF) compared with placebo (EF  mean net difference in E
[placebo EF  baseline], in EF % units).
Abbreviations as in Table 1.f a drug or device on parameters of LV remodeling and longer-term trial-level therapeutic effects on mortality in
VD. Furthermore, these drug/device-induced changes in
entricular remodeling reflect the probability of a categorical
ortality outcome (favorable, neutral, adverse) for those
herapies.
Several individual therapeutic agents with favorable effects
n remodeling, including angiotensin-converting enzyme in-
ibitors (20,42) and beta-adrenergic blockers (85), are associ-
ted with favorable effects on clinical outcomes in HF trials.
onversely, agents such as omapatrilat (5,6) or ibopamine
62,125) with neutral or adverse effects on remodeling relative
o a comparator have been found to be associated with neutral
r adverse effects on clinical outcomes. In distinct trials, the
asopressin V2-receptor antagonist tolvaptan was shown to
ave a neutral effect on both ventricular remodeling and
ong-term clinical outcomes (45,67).
Based in part on such data, it is widely conceptualized
hat ventricular remodeling is biologically related to and
nvolved in the progression of HF (140,141). The relation-
hip is not consistently demonstrated, however. Bozkurt et
l. (120) showed a dose-dependent reverse remodeling effect
ver 3 months with etanercept, a cytokine inhibitor. Three
ears later, a much larger long-term study failed to show any
ared With Placeboin EF Compared With Placebo
EF (95% CI)†
Mean Follow-Up
Weeks [Range]
3.8 (1.7 to 9.2) 60.7 [26–104]
1.9 (1.8 to 2.0) 12
12.0 (4.4 to 19.6) 52
) 4.2 (3.7 to 4.7) 22 [12–52]
2.7 (1.9 to 3.5) 21 [6–26]
4.0 (0.5 to 7.5) 26
3.3 (0.3 to 6.4) 36.7 [12–52]
6.9 (5.8 to 8.0) 30 [13–52]
2.7 (1.2 to 4.1) 48.3 [12–208]
3.7 (1.5 to 5.9) 24 [4–52]
2.0 (0.8 to 4.8) 52
3.4 (0.5 to 6.3) 8.7 [4–16]
4.4 (3.7 to 5.1) 13
4.0 (1.2 to 6.7) 30 [12–52]
3.0 (3.6 to2.4) 10 [8–12]
2.9 (0.8 to 5.0) 39 [26–52]
0.0 (4.9 to 4.9) 5
4.5 (1.8 to 7.1) 25.5 [24–26]
0.5 (2.8 to 3.8) 26
2.2 (1.5 to 2.9) 53
4.0 (0.5 to 8.5) 19
2.5 (0.6 to 4.4) 28.3 [9–52]
3.0 (1.9 to 4.1) 25.7 [8–52]
0.8 (0.3 to 1.9) 54
1.3 (0.7 to 1.9) 78
atic LVD, as this was the only trial that exclusively examined patients
-analysis was used to calculate the absolute change () in ejection
een intervention and placebo groups: [intervention EF  baseline] omphange
ies
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4])
2,708]
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rom a multifactorial and complex process unlikely to be
holly captured by change in a single volume measurement
r serologic parameter (7,142). Although some events that
mpact clinical course are plausibly related to remodeling
such as hospitalization for HF or risk of sudden death),
ther mortal events, such as acute myocardial infarction, are
bsolute Effect of Drug/Device on Change in EDV Compared WithTable 3 Absolute Effect of Drug/Device on Change in EDV Com
Intervention (Ref. #)
No. of Studie
(n [Range])
Bisoprolol (25,41) 2 (188 [28–16
Bucindolol (72,73) 2 (188 [49–13
CRT (74–78,135) 5 (1,086 [34–4
Candesartan (79) 1 (305)
Captopril (81–83,85,136–138) 7 (668 [40–29
Carvedilol (85,86,88–91,95,97,98,103,139) 11 (900 [21–41
Digoxin (106,108) 2 (266 [88–17
Enalapril (20,42,110) 3 (374 [17–30
Enalapril-Prev (21)* 1 (108)
Enoximone (114,115) 2 (44 [20–24])
Etanercept (120) 1 (47)
Felodipine (43,122) 2 (280 [20–26
Hydralazine-ISDN (22) 1 (459)
Ibopamine (125) 1 (18)
Metoprolol CR (39,126,127) 3 (486 [41–42
Prazosin (129,130) 2 (45 [22–23])
Spironolactone (132,133) 2 (143 [37–10
Tolvaptan (45) 1 (240)
Valsartan (38) 1 (5,010)
Enalapril was examined separately when studied in patients with asymptomatic LVD, as this wa
pecific therapy, meta-analysis was used to calculate the absolute change () in end-diastolic volum
roups: [intervention EDV  baseline]  [placebo EDV  baseline], in ml).
Abbreviations as in Table 1.
bsolute Effect of Drug/Device on Change in ESV Compared WithTable 4 Absolute Effect of Drug/Device on Change in ESV Com
Intervention (Ref. #)
No. of Studi
(n [Range]
Bisoprolol (25,41) 2 (188 [28–16
CRT (74–78,135) 5 (1,086 [34–4
Candesartan (79) 1 (305)
Captopril (80–82,84,136–138) 7 (668 [40–29
Carvedilol (85,86,88,89,95,97,98,103,139) 9 (852 [21–41
Digoxin (108) 1 (178)
Enalapril (20,42) 2 (351 [50–30
Enalapril-Prev (21)* 1 (108)
Etanercept (120) 1 (47)
Felodipine (43,122) 2 (280 [20–26
Hydralazine-ISDN (22) 1 (459)
Ibopamine (125) 1 (18)
Metoprolol CR (39,127) 2 (467 [41–42
Prazosin (129,130) 2 (45 [22–23])
Spironolactone (133,134) 2 (143 [37–10
Tolvaptan (45) 1 (240)
Enalapril was examined separately when studied in patients with asymptomatic LVD, as this wa
pecific therapy, meta-analysis was used to calculate the absolute change in end-systolic volume (ES
intervention ESV  baseline]  [placebo ESV  baseline], in ml).
Abbreviations as in Table 1.ikely less related. Thus, the expectation that a single
urrogate marker could predict the effects of a drug or device
n clinical outcomes with high precision is unrealistic.
or this reason, we recognize that the effect of a drug or
evice on LV remodeling, or on any single parameter for
hat matter, is unlikely to achieve the level of precision
iscussed by Prentice (143) or by Fleming and DeMets
bod With Placebo
EDV (95% CI)†
Mean Follow-Up,
Weeks [Range]
52.5 (108.1 to 3.2) 37 [22–52]
37.1 (75.8 to 1.6) 12
31.8 (33.6 to30.0) 19.4 [6–26]
8.2 (232.0 to 215.6) 26
15.4 (19.5 to11.4) 44.4 [25–52]
26.7 (40.5 to13.0) 29.3 [13–52]
9.9 (39.7 to 20.0) 16 [12–20]
11.1 (20.8 to1.4) 30 [12–52]
5.0 (20.0 to 10.0) 52
31.6 (85.0 to 148.3) 10 [4–16]
18.0 (22.7 to13.3) 13
52.7 (161.8 to 56.4) 39 [26–52]
5.6 (19.8 to 8.5) 26
33.9 (43.8 to 111.5) 5
27.6 (63.9 to 8.8) 24.7 [24–26]
4.1 (50.8 to 59.1) 17.5 [9–26]
26.9 (42.3 to11.5) 34.5 [17–52]
3.4 (9.1 to 2.3) 54
0.0 (1.5 to 1.4) 78
ly trial that exclusively examined patients with asymptomatic LVD. †When 1 trial existed for a
) compared with placebo (EDVmean net difference in EDV between intervention and placebo
bod With Placebo
ESV (95% CI)†
Mean Follow-Up
Weeks [Range]
63.0 (111.1 to14.9) 37 [22–52]
25.8 (28.5 to23.2) 19.4 [6–26]
11.3 (222.8 to 200.1) 26
15.7 (21.9 to9.6) 44.4 [25–52]
33.9 (48.4 to19.3) 32.2 [13–52]
19.5 (40.1 to 1.0) 12
19.6 (46.2 to 7.0) 52 [52]
5.0 (18.6 to 8.6) 52
24.3 (28.8 to19.8) 13
55.4 (157.1 to 46.4) 39 [26–52]
8.8 (18.4 to 0.8) 26
28.2 (48.5 to 104.9) 5
30.8 (73.4 to 11.7) 25 [24–26]
4.3 (62.2 to 53.5) 17.5 [9–26]
27.7 (31.3 to24.0) 34.5 [17–52]
5.4 (12.2 to 1.4) 54
ly trial that exclusively examined patients with asymptomatic LVD. †When 1 trial existed for a
pared with placebo (ESVmean net difference in ESV between intervention and placebo groups:Placepare
s
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ather, the data from this analysis suggest that drug/
evice effects on remodeling should be viewed as sugges-
ive of the intervention’s potential effect on mortality.
iven the demonstrated proportional relationship be-
ween drug/device effects on short-term ventricular re-
odeling and long-term mortality, it is reasonable to
Figure 2 Relationship Between Drug/Device Effect on EF and M
of Categorical Mortality Outcome Based on Drug/Dev
(A) Quantitative relationship between drug/device effects on ejection fraction (EF)
individual remodeling trial plotted against the mortality odds ratio (OR) for the spe
Table 1. Interventions were classified as favorable (blue circles) if the upper limit
1, neutral (black circles) if the 95% CI crossed 1, and adverse (red circles) if t
term therapeutic effect on left ventricular EF and longer-term therapeutic effect on
randomized controlled trials (RCTs) of 25 interventions, involving 19,092 patients.
effect on EF: the lines represent the likelihood of a categorical mortality outcome
weighted, ordered logistic regression). Color-coded mortality effect based on data
tion as described in A. The graph suggests that if the mean change in EF is 10% i
significantly favorable (blue line), neutral (black line), or significantly unfavorableonclude that the effects of a drug or device on LV temodeling can be taken into consideration during the
evelopment process of novel therapeutic agents for HF,
n creating a probability signal of the likelihood of a
avorable, neutral, or adverse effect of the therapy being
nvestigated on longer-term mortality outcomes.
tudy limitations. There are important limitations to this
nalysis. Inherent in this retrospective analysis of prospec-
lity, and Predicted Probability
ffect on EF
ortality: each data point represents a placebo-corrected change in EF from an
erapy. Color-coded mortality effect based on data from mortality trials listed in
95% confidence interval (CI) of the OR for death from the mortality trials was
er limit of the 95% CI was 1. There was a significant correlation between short-
lity (r  0.51, p  0.001). Remodeling data were derived from analysis of 86
redicted probability of a categorical mortality outcome based on drug/device
on an intervention’s trial-level effect on EF compared with placebo (unadjusted,
ortality trials listed in Table 1. Definition of mortality effect for a given interven-
short-term studies, the probabilities that the long-term mortality studies will be
e) are approximately 85%, 15%, and 1%, respectively.orta
ice E
and m
cific th
of the
he low
morta
(B) P
based
from m
n the
(red linive studies are both publication bias and selection bias. To
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rials that fit rigorous inclusion criteria (recognizing that
ome potentially relevant works might be excluded from the
nalysis). Publication bias poses threats to all meta-
pidemiological studies, including this study. It may be less
f a problem for the mortality trials, because large RCTs
ay be published irrespective of their findings. Even if
Figure 3 Quantitative Relationship Between Drug/Device Effec
and Predicted Probability of Mortality by Drug/Device
(A) Quantitative relationship between drug/device effects on end-diastolic volume
from an individual remodeling trial plotted against the mortality OR for the specific
1: favorable (blue circles), neutral (black circles), or adverse (red circles). Defini
a significant correlation between effect sizes in the mortality trials and mean thera
ysis of 50 randomized controlled trials (RCTs) of 19 interventions, including 10,85
drug/device effect on EDV: the lines represent the likelihood of a categorical mort
cebo (unadjusted, weighted, ordered logistic regression). Color-coded mortality effe
a given intervention is as described in Figure 2A. The graph suggests that if the m
term mortality studies will be significantly favorable (blue line), neutral (black line
respectively.ublication bias is a problem for remodeling trials, it is tnclear whether it would affect the associations described,
nd to which direction. Nonpublication of neutral remod-
ling trials would have no systematic effect on our results for
nterventions with a neutral effect on mortality, but it would
ias our results away from the null for interventions with
dverse or favorable effects on mortality. Moreover, pub-
ished studies of remodeling are analyses of “completers,”
EDV and Mortality,
ct on EDV
and mortality: each data point represents a placebo-corrected change in EDV
y. Color-coded mortality effect based on data from mortality trials listed in Table
mortality effect for a given intervention is as described in Figure 2A. There was
uced changes in EDV (r  0.44, p  0.002). Remodeling data derived from anal-
l patients. (B) Predicted probability of a categorical mortality outcome based on
utcome based on an intervention’s trial-level effect on EDV compared with pla-
ed on data from mortality trials listed in Table 1. Definition of mortality effect for
ange in EDV is 10 ml in the short-term studies, the probabilities that the long-
significantly unfavorable (red line) is approximately 56%, 43% and 1%,ts on
Effe
(EDV)
therap
tion of
py-ind
5 tota
ality o
ct bas
ean ch
), andhat is, patients who have both baseline and final data for
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July 27, 2010:392–406 Ventricular Remodeling and Ef fects on Mortalitynalysis. It is difficult to predict the effect of the “noncom-
leters” on the analysis if their information was available. If
nything, data from noncompleters would attenuate the
Figure 4 Quantitative Relationship Between Drug/Device Effec
and Predicted Probability of Favorable Outcome Base
(A) Quantitative relationship between drug/device effects on end-systolic volume (
an individual remodeling trial plotted against the mortality OR for the specific thera
favorable (blue circles), neutral (black circles), or adverse (red circles). Definitio
significant correlation between effect sizes in the mortality trials and the effect siz
derived from analysis of 40 randomized controlled trials (RCTs) of 16 interventions
come based on drug/device effect on ESV. The blue line represents the likelihood
compared with placebo (unadjusted weighted logistic regression). There was insuf
comes individually. Color-coded mortality effect based on data from mortality trials
in Figure 2A. The graph suggests that if the mean change in ESV is 25 ml in the
cantly favorable is approximately 20%. This is equivalent to stating that the probab
approximately 80% (100%  20%).verage EF, EDV, or ESV changes toward the unfavorable rirection. It is likely that this shift would be influential only
f a substantial proportion of patients had died in the
emodeling studies. The median proportion of deaths in the
ESV and Mortality,
Drug/Device Effect on ESV
nd mortality: each data point represents a placebo-corrected change in ESV from
lor-coded mortality effect based on data from mortality trials listed in Table 1:
ortality effect for a given intervention is as described in Figure 2A. There was a
ESV in the remodeling studies (r  0.48, p  0.002). Remodeling data are
ding 5,435 total patients. (B) Predicted probability of a favorable mortality out-
avorable mortality outcome based on an intervention’s trial-level effect on ESV
remodeling data for ESV to model the probability for neutral or adverse out-
in Table 1. Definition of mortality effect for a given intervention is as described
-term studies, the probability that the long-term mortality studies will be signifi-
at the long-term mortality studies are neutral or significantly unfavorable ists on
d on
ESV) a
py. Co
n of m
es on
, inclu
of a f
ficient
listed
short
ility themodeling studies was 3.6%, (25th and 75th quartiles, 0%
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nformation. These numbers suggest that the effects of
oncompleters on our analyses would not likely be dramatic.
Second, most data pertain to EF. We approximated
hanges in LV volume-related outcomes (EDV, ESV) from
ata on LV indexes and diameters in the majority of
ertinent studies. As discussed in Methods, the concor-
ance of the approximations and the derived data was not
ood in a small number of examples. All analyses were
onsignificant among the 14 trials that directly reported
DV and ESV measurements, but this could be attributed
o substantial loss of statistical power. Therefore, results on
V volumes should be viewed with caution, and there are
nsufficient data to draw any conclusions regarding which of
he parameters in this analysis may best correlate with
ortality outcomes. Additionally, most of the trials evalu-
ted remodeling using radionuclide ventriculography or
-dimensional echocardiography. In clinical practice,
-dimensional echocardiography, with its inherent limita-
ions, is predominantly utilized. While we recognize that
ore contemporary techniques, such as 3-dimensional
chocardiography, contrast echocardiography, and cardiac
agnetic resonance imaging would more precisely measure
olumes, these techniques have not as yet been widely
eployed for use in multicenter trials, and were not used for
he drugs and devices that were included in this analysis.
Third, we grouped results from trials spanning different
herapeutic eras and were heterogeneous in their follow-up
uration, ranging from 4 weeks to 1 year. This was
xpected, as there is no generally established time frame for
he ideal assessment of an intervention’s effect on ventricular
emodeling. External validation is not yet available for these
esults that represent the current published literature.
Fourth, our analyses are sensitive to confounding and to
cological fallacies. Ideally, we would associate changes in
he remodeling outcomes and corresponding changes in the
linical outcomes measured in the same patients. If individ-
al patient data are available, one can use structural equation
odeling or path analysis methodologies. If sufficient sum-
ary statistics are available, one can use specially developed
eta-analytic techniques (145). However, in most cases,
ncluding the current one, such data are not available. We
elieve that even ecological associations are of interest
ecause they can help formulating hypotheses for further
tudy.
In addition, we acknowledge that our analyses do not
rove the validity of remodeling outcomes as surrogate
utcomes for mortality in LVD, as defined by others
143,144), and indeed, we believe the data suggest that
o serum biomarker or cardiac structural marker will do
o, given the complexity of the HF syndrome. Rather, the
ata suggest a quantifiable association of a marker such as
emodeling and a longer-term outcome such as mortality,
hich may be a useful signal in the therapeutic develop-
ent process. We acknowledge the possibility that theres indeed a stronger relationship between remodeling andortality, and that the limitations of our approach given
he available data obfuscate our ability to discern such a
elationship, particularly within an individual interven-
ion. The modest correlation of the remodeling effect of
nterventions with the mortality effect seen in this anal-
sis is influenced by both the underlying inherent relation
etween the therapeutic effect on remodeling on mortal-
ty, as well as the fact that different interventions will
ave various proportions of their effect mediated through
remodeling mechanism.
Finally, the analyses of changes in LVEF and volumes
eported in the literature and summarized here do not allow
clear distinction between a simple functional change in EF
r volumes and a true long-term structural change in the
nderlying LV architecture resulting from therapy (what
ould truly be considered remodeling). To assess the latter,
study design needs to include a “withdrawal” study, in
hich EF and volumes are reassessed after withdrawal of
rug or device influence. Some published studies indeed
eport such results (20,21,45), although the vast majority of
emodeling studies do not.
onclusions
ence, based on analysis of the current literature investi-
ating patients with LVD, there is a significant correlation
nd a salient predictability signal between short-term trial-
evel therapeutic effects on LV remodeling and longer-term
rial-level therapeutic effects on mortality. Our findings
ndicate that the effect of a drug or device on LV remodeling
an be viewed as a probability signal of outcome effects of
hose therapies during the development process of novel
herapeutic agents for the treatment of HF, rather than as a
recise surrogate. Although no surrogate end point, alone,
ill ever fully substitute for a mortality assessment, our
ndings of an increased probability of a survival benefit for
n intervention associated with improvements in remodel-
ng parameters imply that the demonstration of favorable
emodeling renders a survival signal more credible. More-
ver, further development of this dataset may allow for
uantitative modeling to predict a new agent’s likelihood of
ortality benefit given the agent’s short-term effect on
emodeling parameters.
eprint requests and correspondence: Dr. James E. Udelson,
ivision of Cardiology, Tufts Medical Center, 750 Washington
treet, Box 70, Boston, Massachusetts 02111. E-mail: judelson@
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